Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Hereditary Angioedema (HAE)

05 November 2011 Study Shows C1-Esterase Inhibitor Concentrate Is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location

C1-esterase inhibitor (C1-INH) concentrate at 20 U/kg is a safe and effective therapy for the long-term treatment of successive acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to final data presented today at the 2011 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Additional data presented at the meeting confirms that C1-INH concentrate provided consistent and reliable treatment response in patients treated for multiple successive HAE attacks at any body location.

> Read More
25 August 2011 CSL Behring Receives European Health Authorities’ Approval for Self-Administration of Berinert®

CSL Behring today announced that European health authorities have approved self-administration of Berinert®, a C1-esterase inhibitor (C1-INH) concentrate indicated in Europe for the treatment of acute attacks of hereditary angioedema (HAE), a rare, serious, and sometimes life-threatening genetic disorder.

> Read More
01 June 2010 CSL Behring Receives Canadian Notice of Compliance for Berinert®

CSL Behring Canada announced today that it has received Notice of Compliance for Berinert® (Human C1 Esterase Inhibitor). The company may now market Berinert for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) of moderate and severe intensity. HAE is a rare and serious genetic disorder.

> Read More
27 May 2010 CSL Behring announces completion of national marketing authorizations of Berinert® after MRP in 23 European countries

CSL Behring announced today it has been granted national marketing authorization in Italy and Luxembourg to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. This latest authorization brings to 28 the number of countries (in Europe, Asia, North America, South America and Australia) in which Berinert is now licensed.

> Read More
01 March 2010 Surveys Reveal High Frequency of Prodromal Symptoms Prior to Acute Hereditary Angioedema Attacks

Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of their HAE attacks, according to survey findings presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. According to researchers, this high frequency suggests that prodromal symptoms may reliably indicate when to initiate treatment to help prevent an acute HAE attack.

> Read More
Page 3 of 7 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+